Long QT Syndrome clinical trials

The registry lists 101 studies for Long QT Syndrome across more than 10 countries. 20 are recruiting or about to start. 72 of them are mainly about Long QT Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-03.

Get an email when these change. Save the Long QT Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 61
Recruiting: 14
Status unknown: 12
Terminated: 8
Enrolling by invitation: 5
Not yet recruiting: 1

Phase

Phase 1: 13
Phase 2: 6
Phase 4: 5
Phase 3: 2

Where

United States: 44
France: 14
Canada: 9
United Kingdom: 5
Israel: 5
Germany: 4

Who runs them

Gilead Sciences (5) · University of British Columbia (5) · Nantes University Hospital (3) · Tel-Aviv Sourasky Medical Center (3) · KU Leuven (3) · Thryv Therapeutics, Inc. (3) · Indiana University (3) · University Hospital, Montpellier (3)

What is being tested here

Drugs under test in Long QT Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
THRV-1268	1	1	1
Eleclazine	0	1	5
Moxifloxacin	0	0	3
Progesterone	0	0	2
Testosterone	0	0	2
Ranolazine	0	0	2
Diltiazem	0	0	1
Lumacaftor	0	0	1
Ivacaftor	0	0	1
Methadone	0	0	1

Coming up

1phase 3 study under way

2studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 2, phase 3 first

Jun 2027Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3) · Phase 3 · Thryv Therapeutics, Inc.
Dec 2026Continuous Versus Intermittent cARdiac Electrical moNitorinG · Washington University School of Medicine

Who these studies take

Of the 14 Long QT Syndrome studies recruiting now, 10 (71%) set no upper age limit and 3 (21%) stop at 75 or younger. 6 (43%) take children under 18. 1 (7%) are for women only and 0 (0%) for men only; 3 (21%) take healthy volunteers.

Recruiting studies that take each age, of 14
Age	Women	Men
10	4 (29%)	4 (29%)
18	13 (93%)	12 (86%)
30	13 (93%)	12 (86%)
40	12 (86%)	11 (79%)
50	12 (86%)	11 (79%)
65	11 (79%)	10 (71%)
75	11 (79%)	10 (71%)
85	11 (79%)	10 (71%)

Across all 101 studies, recruiting or not: 43% stop at 75 or younger and 40% at 65; 41% take children; 5% are for women only and 5% for men only; 36% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Long QT Syndrome studies take

Of 21 observational studies under Long QT Syndrome, half reached primary completion within 56 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Interventional, no phase	18 mo6–28 · 15 studies	—	—
Observational	56 mo26–81 · 21 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 101. Browse all 101 → or search them.